Login to Your Account

Astellas buys GPCR drug developer Ogeda for €500M up front

By Michael Fitzhugh
Staff Writer

Monday, April 3, 2017

Astellas Pharma Inc. is buying Belgium's Ogeda SA for €500 million up front and up to €300 million in milestone payments tied to the clinical and regulatory advancement of fezolinetant.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription